Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Polvere
M Nappi

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Pharmacotherapy|December 22, 1999
Vitamins for the management of cardiovascular disease: a simple solution to a complex problem?S E Lenhart, J M Nappi
The Annals of Pharmacotherapy|November 1, 1993
Sotalol: a breakthrough antiarrhythmic?J M Nappi, P L McCollam
The Annals of Pharmacotherapy|June 1, 1993
Concomitant amiodarone and the implantable cardioverter-defibrillator: is there a place?P L McCollam, J M Nappi
American Journal of Hospital Pharmacy|June 1, 1981
Review of a new gastrointestinal drug--metoclopramideC D Ponte, J M Nappi
Clinical Therapeutics|December 25, 2003
The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonistKelli L Davis, Jean M Nappi
Pharmacy Practice|August 22, 2014
A retrospective characterization of worsening renal function in patients with acute decompensated heart failure receiving nesiritideJessica A Starr, Jean M Nappi
Pharmacotherapy|July 1, 1985
Flecainide: a new prototype antiarrhythmic agentJ M Nappi, J L Anderson
Journal of Virology|July 23, 2002
Multiple transmembrane amino acid requirements suggest a highly specific interaction between the bovine papillomavirus E5 oncoprotein and the platelet-derived growth factor beta receptorValerie M Nappi, Lisa M Petti
The Annals of Pharmacotherapy|July 5, 2003
Bosentan for the treatment of pulmonary arterial hypertensionKenneth W Kenyon, Jean M Nappi
The Annals of Pharmacotherapy|March 16, 2002
Role of race in the pharmacotherapy of heart failureJames S Kalus, Jean M Nappi
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Pharmacotherapy|December 22, 1999
Vitamins for the management of cardiovascular disease: a simple solution to a complex problem?S E Lenhart, J M Nappi
The Annals of Pharmacotherapy|November 1, 1993
Sotalol: a breakthrough antiarrhythmic?J M Nappi, P L McCollam
The Annals of Pharmacotherapy|June 1, 1993
Concomitant amiodarone and the implantable cardioverter-defibrillator: is there a place?P L McCollam, J M Nappi
American Journal of Hospital Pharmacy|June 1, 1981
Review of a new gastrointestinal drug--metoclopramideC D Ponte, J M Nappi
Clinical Therapeutics|December 25, 2003
The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonistKelli L Davis, Jean M Nappi
Pharmacy Practice|August 22, 2014
A retrospective characterization of worsening renal function in patients with acute decompensated heart failure receiving nesiritideJessica A Starr, Jean M Nappi
Pharmacotherapy|July 1, 1985
Flecainide: a new prototype antiarrhythmic agentJ M Nappi, J L Anderson
Journal of Virology|July 23, 2002
Multiple transmembrane amino acid requirements suggest a highly specific interaction between the bovine papillomavirus E5 oncoprotein and the platelet-derived growth factor beta receptorValerie M Nappi, Lisa M Petti
The Annals of Pharmacotherapy|July 5, 2003
Bosentan for the treatment of pulmonary arterial hypertensionKenneth W Kenyon, Jean M Nappi
The Annals of Pharmacotherapy|March 16, 2002
Role of race in the pharmacotherapy of heart failureJames S Kalus, Jean M Nappi
Pageof 6